<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Endoscopic therapies for early <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> may be a viable alternative to esophagectomy </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: Our purpose was to compare endoscopic therapy and esophagectomy </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN: Retrospective review from a single institution </plain></SENT>
<SENT sid="3" pm="."><plain>SETTING: A medium-sized tertiary referral center </plain></SENT>
<SENT sid="4" pm="."><plain>PATIENTS AND INTERVENTIONS: <z:hpo ids='HP_0000001'>All</z:hpo> patients with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or intramucosal <z:mp ids='MP_0002038'>carcinoma</z:mp> treated by photodynamic therapy (<z:chebi fb="7" ids="53228">PDT</z:chebi>), EMR, or <z:chebi fb="17" ids="49474,49475">argon</z:chebi> plasma coagulation (APC) or esophagectomy with curative intent from May 1998 until November 2005 </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASUREMENTS: Survival, progression to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, eradication of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, major and minor complications, and costs were compared </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Sixty-two patients who underwent endoscopic therapy (2 APC alone, 18 EMR + APC, 20 PDT + APC, and 22 EMR + <z:chebi fb="7" ids="53228">PDT</z:chebi> + APC) and 32 patients who underwent esophagectomy met the inclusion criteria </plain></SENT>
<SENT sid="7" pm="."><plain>The 30-day mortality rate included 1 patient in the endotherapy group (2%) and none in the surgical group (P = .49) </plain></SENT>
<SENT sid="8" pm="."><plain>No <z:hpo ids='HP_0011420'>deaths</z:hpo> from <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> occurred in either group </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> developed in 6% of endotherapy patients and in none in the surgical cohort (P &lt; .05) </plain></SENT>
<SENT sid="10" pm="."><plain>Major and minor complications occurred in 8% and 31% of endotherapy patients, respectively, and 13% and 63% of surgery patients (P = .50, P &lt; .001) </plain></SENT>
<SENT sid="11" pm="."><plain>Median cost to date was $40,079 for endotherapy and $66,060 for esophagectomy (P &lt; .001) </plain></SENT>
<SENT sid="12" pm="."><plain>LIMITATIONS: Retrospective study, relatively short follow-up, small numbers </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Both endotherapy and esophagectomy can effectively treat high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and intramucosal <z:mp ids='MP_0002038'>carcinoma</z:mp> associated with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Endotherapy is associated with a higher risk of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e>, although this is uncommon </plain></SENT>
<SENT sid="15" pm="."><plain>Esophagectomy incurs higher initial costs and results in more frequent minor complications but is usually curative </plain></SENT>
</text></document>